Sign in

CIK 0001390478

  • Non-accelerated filer
  • Smaller reporting company

SELLAS Life Sciences Group, Inc.

Sign in to watch
Ticker
SLS
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
FY end
Dec 31
Incorporated
DE
Entity type
Operating
Phone
+1 646-200-5278
Business address
7 TIMES SQUARE, SUITE 2503, NEW YORK, NY, 10036
Former names
GALENA BIOPHARMA, INC., Galena Biopharma, Inc., RXI PHARMACEUTICALS CORP
Open-market buys, last 90 days
$0
in 0 filings
Open-market sales, last 90 days
$716,682
in 3 filings

Net −$716,682. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.

Date Insider Transaction Shares Price Value Owned after
2026-11-18 CICIC DRAGAN SVP, Chief Development Officer Sale −6,933 $19.18 $133K 557,361
2026-01-07 CICIC DRAGAN SVP, Chief Development Officer Grant or award +300,000 557,805
2025-12-03 CICIC DRAGAN SVP, Chief Development Officer Other disposition −63,800 $1.50 $96K 257,805
2025-01-10 CICIC DRAGAN SVP, Chief Development Officer Grant or award +113,000 228,328
2025-01-10 CICIC DRAGAN SVP, Chief Development Officer Grant or award +81,300 309,628
2025-01-10 CICIC DRAGAN SVP, Chief Development Officer Grant or award · Stock Option (Right to Buy) +169,500 169,500
2024-12-04 CICIC DRAGAN SVP, Chief Development Officer Other disposition −8,256 $1.13 $9K 115,328

Page 1 of 1 · 7 trades